Introducere

1. 111= Dr. Haras Monica Andreia, 2012, Particularități ale osteoporozei la pacienții cu
tireotoxicoze, Teză de doctorat - rezumat

2. 5= Manuela Russu, 2007, Seria Ghiduri Clinice pentru Obstretică și Ginecologie.

Terapia menopauzei

3. 10= Corina Cristina Morcov, 2012, Influenţa compoziţiei corporale şi a greutăţii asupra
masei osoase. Obezitatea şi densitatea minerală osoasă, Lucrare doctorat, p.132-144

1. 4= Prof. Dr. Eusebie Zbranca, 2008, Endocrinologie: ghid de diagnostic și tratament

în bolile endocrine, Ediția a III-a, p.207-225,382-389

Cap 1

27= Haulică I. Fiziologie umană, ediția a III-a. București, ed. Polirom,2007, 664-667.

35= Jerca L, Ungureanu D. Biochimia hormonilor, ed. Terra Nostra, Iași 2001, 194-204.

50= Patel S, Homaei A, Raju AB, Meher BR. Estrogen: The necessary evil for human
health, and ways to tame it. Biomedicine & Pharmacotherapy. 2018 Jun30;102:403-11.

76= Zbranca E, Mogoș V, Găleșanu C, Vulpoi C, Endocrinologie,Ghid de diagnostic și

tratament în bolile endocrine, ed. Polirom,2008,345-358.

11= Chang MS. Dual roles of estrogen metabolism in mammary carcinogenesis. BMB
reports. 2011;44(7):423-34.

53= Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by

conjugation. JNCI Monographs. 2000 Jul 1;2000(27):113-24.

51= Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERα)
and beta (ERβ): subtype-selective ligands and clinical potential. Steroids. 2014 Nov15;90:13-
29.
69= Wang ZY, Yin L. Estrogen receptor alpha-36 (ER-α36): A new player in human breast
cancer. Molecular and cellular endocrinology. 2015 Dec 15;418:193-206.

23= Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocrine
reviews. 2007 Oct 4;28(7):726-41.

Hăulică Haulică I. Fiziologie umană, ediția a III-a. București, ed. Polirom,2007, 664-667.

Cap 2 toate sunt cu 200 in fata

Poza 210= G. Donald Whedon, Robert Proulx Heaney, ENCYCLOPEDIA BRITANNICA,

2012, Bone anatomy

Os 200= cautare poza

Poza 211 OpenStax College , Illustration from Anatomy & Physiology, Jun 19, 2013.

Poza 212

Poza 213= 3 cu wiliam

1. 201 Zbranca ( pag 204 la structura si functie) Eusebie Zbranca, Endocrinologie ghid
de diagnostic și tratament în bolile endocrine, ediția a III-a, Iași, Ed. Palindrom, 2008,
204

2. 202 Prof. Univ. Dr. Paulina Ciurea, Conf. Univ. Dr. Anca Roșu, Prep. Univ. Dr.
Anca Mușetescu, Prep. Univ. Dr. Florentin Vreju, 2007, Reumatologie, p. 415-439
3. Williams KB & DeLuca HF. Characterization of intestinal phosphate absorption using
a novel in vivo method. Am.J.Physiol Endocrinol.Metab 2007 292 E1917-E1921.
4. 2. Shoback D, Sellmeyer D & Bikle DD. Metabolic Bone Disease. In Greenspan's
basic and clinical endocrinology, ch. 8, pp 227-285. Eds D Gardner & D Shoback: Mc
Graw Hill, 2011.
5. 3. Feldman D, DJ M, A K & E B. Vitamin D: Biology, Action, and Clinical
Implications. In Osteoporosis, edn 2 nd, ch. 13, pp 317-382. Eds R Marcus, D
Feldman, N A & C Rosen: Elsevier, 2001.
6. 4. Clarke B. Normal bone anatomy and physiology. Clin.J.Am.Soc.Nephrol. 2008 3
Suppl 3 S131-S139.
7. 5. Burr DB. Targeted and nontargeted remodeling. Bone 2002 30 2-4.
8. 6. Bartl R & Frisch B. Biology of bone. In Osteoporosis, edn 2nd, ch. 2, pp 7-28. Eds
R Bartl & B Frisch: Springer, 2009.
 9. 7. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R
& National Osteoporosis F. Clinician's Guide to Prevention and Treatment of
Osteoporosis. Osteoporos Int 2014 25 2359-2381

Osteoporoză

Fig 11 =100. Wright NC, Looker A, Saag K, Curtis JR, Dalzell ES, Randall S, Dawson-
Hughes B. The recent prevalence of osteoporosis and low bone mass based on bone mineral
density at femoral neck or lumber spine in the United States. J Bone Miner Res 2014.

101 .Cîrstoiu C. Osteoporoza în menopauză. Ed. II, Ed. Univ. „Carol Davila” București, 2013.

102. Cummings SR, Melton III LJ. Epidemiology and outcomes of osteoporotic fractures.
Lancet 2002;359:1761-7.

10 3. WHO Study Group. Assessment of fracture risk and its application to postmenopausal
osteoporosis.World Health Organ Tech Ser 1984;843.

104. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet
2002;359:1929-36.

105. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in the
elderly trial (PROFET): a randomised controlled trial. Lancet 1999;353:93-7.

106. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and
adolescents: a review of controlled trials. Bone, 2007;40(1):14- 27.

107. Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin
Rheumatol 2005; 19:1007-19.

108. Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr

Opinion Rheumatol 2005; 17:456-61.

1. 9 . Prof. Dr. Eusebie Zbranca, 2008, Endocrinologie: ghid de diagnostic și tratament

în bolile endocrine, Ediția a III-a, p.207-225,382-389
10. Kanis JA – Diagnosis of osteoporosis and assessment of fracture risk, Lancet 2002,
359: 1929-1336
11. Dr. Vasile Ionuț Silviu, 2011, Studiul modificărilor masei osoase și ale markerilor
metabolismului osos în osteoporoza tiroxinică. Implicații terapeutice, Lucrare doctorat
– Rezumat, p. 8-11
12 Mazess RB 1987 Bone density in diagnosis of osteoporosis: Thresholds and
breakpoints. Calcif Tissue Int 41: 117-1 18.
12 M. Suta, 2006, Evaluarea fracturilor vertebrale osteoporotice, Romanian Journal of
Rheumatology
13. Dumitrache C, Ionescu B., 2002, Endocrinologie clinică. Ediţia a II-a revizuită şi
completată. Ed. Medicală Naţională, Bucureşti
14. Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of
osteoporosis. Am J Med 1994; 646–650.
15. 2. Johnell O., Kanis J.A. (2006) An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726–1733.
16. Kanis,J.A., McCloskey,E.V., Johansson,H., Cooper,C., Rizzoli,R., & Reginster,J.Y.
(2013)European guidance for the diagnosis and management of osteoporosis in
postmenopausal women. Osteoporos.Int. 24, 23-57.
17. Kannus,P., Sievanen,H., Palvanen,M., Jarvinen,T., & Parkkari,J. (2005) Prevention of
fall and consequent injuries in elderly people. Lancet 366, 1885-1893.
18. Ooms,M.E., Roos,J.C., Bezemer,P.D., van der Vijgh,W.J., Bouter,L.M., & Lips,P.
(1995)Prevention of bone loss by vitamin D supplementation in elderly women: a
randomized doubleblindtrial. J.Clin.Endocrinol.Metab 80, 1052-1058.
19. Bischoff-Ferrari,H.A., Dietrich,T., Orav,E.J., & Dawson-Hughes,B. (2004b)
20. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a
population-based study of younger and older adults. Am.J.Med. 116, 634-639.
21. Bischoff-Ferrari,H.A. (2012) Vitamin D and fracture prevention.
Rheum.Dis.Clin.North Am. 38, 107-113.
22. Dawson-Hughes,B., Mithal,A., Bonjour,J.P., Boonen,S., Burckhardt,P., Fuleihan,G.E.,
Josse,R.G., Lips,P., Morales-Torres,J., & Yoshimura,N. (2010) IOF position
statement: vitamin D recommendations for older adults. Osteoporos.Int. 21, 1151-
1154.
23. Stockton,K.A., Mengersen,K., Paratz,J.D., Kandiah,D., & Bennell,K.L. (2011) Effect
of vitamin D supplementation on muscle strength: a systematic review and meta-
analysis. Osteoporos.Int. 22, 859-871.
24. Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of
osteoporosis. Am J Med 1994; 646–650.
25. 2. Johnell O., Kanis J.A. (2006) An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726–1733.
26. 3. Melton III L.J., Kallmes D.F. Epidemiology of vertebral fractures: Implications
for vertebral augmentation. Acad radiol. 2006; 13:538-45.
27. 4. Nevitt M.C., Ettinger B., Black D.M. et al. The association of radiologically
detected vertebral fractures with back pain and function: a prospective study. Ann
Intern Med 1998;128:793-800.
28. 5. Kanis J.A., Oden A., Johnell O. et al. The components of excess mortality after
hipfracture. Bone 2003; 32:468–473.
29. 6. Cooper C., Atkinson E.J., Jacobsen S.J., O’Fallon W.M., Melton L.J. A
population base study of survival after osteoporotic fractures. Am J Epidemiol 1993;
137:1001–1005.
30. 7. Kanis J.A., McCloskey E.V., Johansson H. et al. European guidance for the
diagnosis and management of osteoporosis în postmenopausal women. Osteoporos
Int. 2013; 24:23–57. doi: 10.1007/s00198-012-2074-y.
31. 8. Stevenson M., Lloyd Jones M., De Nigris E. et al. A systematic review and
economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide
for the prevention and treatment of postmenopausal osteoporosis. Health Technol
Assess 2005; 9:1–160.
32. 9. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N
Engl J Med 2010; 362:1825.
 33. 10. Fedele S., Porter S.R., D‘Aiuto F., et al. Nonexposed variant of bisphosphonate-
associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123:1060.
34. 11. Meunier P.J., Slosman D.O., Delmas P.D., et al. Stronţium ranelate: dose-
dependent effects în established postmenopausal vertebral osteoporosis - a 2-year
randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060.
35. 12. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Stronţium ranelate reduces
the risk of nonvertebral fractures în postmenopausal women with osteoporosis:
Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab
2005; 90:2816.
36. 13. J.M. Kaufman, M. Audran, G. Bianchi et al. Effi cacy and Safety of Stronţium
Ranelate în the Treatment of Osteoporosis în Men. JCEM 2013; 98:592-
601;doi:10.1210/jc.2012-3048.
37. 14. European Medicines Agency. EMEA recommends changes în the product
information for Protelos/Osseor due to the risk of severe hypersensitivity reactions.
Press Release (2007). http://www.emea.
europa.eu/docs/en_GB/document_library/Press_release/2009/11/ WC500015592.pdf.
38. 15. Jonville-Bera A.P., Autret-Leca E. Adverse drug reactions of strontium
ranelate(Protelos(®) în France. Presse Med 2011;40:e453.
39. 16. Osborne V., Layton D., Perrio M., et al. Incidence of venous thromboembolism
în users of stronţium ranelate: an analysis of data from a prescription-event monitoring
study în England. Drug Saf 2010;33:579.
40. 17. Recommendation to restrict the use of Protelos / Osseor (strontium ranelate).
http://www.ema.europa.eu/docs/en_GB/document_library/
Press_release/2013/04/WC500142507.pdf.
41. 18. Neer R.M., Arnaud C.D., Zanchetta J.R. et al. Effect of parathyroid hormone
(1–34) on fractures and bone mineral density în postmenopausal women with
osteoporosis. N Engl J Med 2001; 344:1434–1441.
42. 19. Prince R., Sipos A., Hossain A. et al. Sustained nonvertebral fragility fracture
risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;
20:1507–1513.
43. 20. Nakamura T., Sugimoto T., Nakano Tet al. Randomized Teriparatide (Human
Parathyroid Hormone (PTH) 1-34) Once-Weekly Effi cacy Research (TOWER) trial
for examining the reduction în new vertebral fractures în subjects with primary
osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097–
3106.doi:10.1210/jc.2011-3479.
44. 21. Joel S. Finkelstein, Jason J. Wyland, Benjamin Z. Leder et al. Effects of
Teriparatide Retreatment în Osteoporotic Men and Women. JCEM 2009; 94:2495-
2501; doi:10.1210/jc.2009-0154.

Cap 3

20= Grindler N, Al-Safi Z, Santore N. Menopausal hormone therapy. Menopause and Hormone
Replacement Therapy. 2016 Jul 20;381-384.
65 Swords KE. Hormone Therapy for Menopausal Women in the Primary Care Setting. The
Journal for Nurse Practitioners. 2017 Sep 30;13(8):562-9.

1. Prof. Dr. Mihai Pricop, 2008, Curs de obstretică și ginecologie. Ginecologia, Ediția a
II-a, p.167-176
2. Prof. Dr. Eusebie Zbranca, 2008, Endocrinologie: ghid de diagnostic și tratament în
bolile endocrine, Ediția a III-a, p.207-225,382-389
3. Dr. Andrei Martin, 2006, Osteoporoza postmenopauză - mecanisme patogenice,
Articol din publicația Medicina Modernă, p. 1-5 9

37= Khosla S, Melton III LJ, Riggs BL. The unitary model for estrogen deficiency and the
pathogenesis of osteoporosis: is a revision needed? Journal of Bone and Mineral Research. 2011
Mar;26(3):441-51.

5. Cîrstoiu C. Osteoporoza în menopauză. Ed. II, Ed. Univ. „Carol Davila” București, 2013.

6. Cummings SR, Melton III LJ. Epidemiology and outcomes of osteoporotic fractures.
Lancet 2002;359:1761-7.

7. WHO Study Group. Assessment of fracture risk and its application to postmenopausal
osteoporosis.World Health Organ Tech Ser 1984;8437.

8. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet

2002;359:1929-36.

9. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in the

elderly trial (PROFET): a randomised controlled trial. Lancet 1999;353:93-7.

10. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and
adolescents: a review of controlled trials. Bone, 2007;40(1):14- 27.

11. Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin
Rheumatol 2005; 19:1007-19.

12. Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr

Opinion Rheumatol 2005; 17:456-61
Deficienta hormonilor estrogeni in osteoporoza

13. Gowen M, Wood DD, lhrie EJ, McGuire MKB, Russell RGG
1983 An interleukin-I -like factor stimulates bone resorption in
vitro. Nature 306378-380.
14. Lorenzo JA, Sousa SL, Alander C, Raisz LG, Dinarello CA
1987 Comparison of the bone-resorbing activity in the supernatants
from phytohemaglutinin-stimulated human peripheral
blood mononuclear cells with that of cytokines through the use
of an antiserum to interleukin 1. Endocrinology 121:1164-
1 170.
15. Gowen M, Wood DD, Russell RGG 1985 Stimulation of the
proliferation of human bone cells in vitro by human monocyte
products with interleukin-] activity. J CIin Invest 751223-1229.
16. Canalis E 1986 Interleukin-1 has independent effects on deoxyribonucleic
acid and collagen synthesis in cultures of rat
calvariae. Endocrinology 118:74-81.
17. Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA,
Heeley JD 1987 Interleukin-1 P is a potent inhibitor of bone
formation in vitro. J Bone Miner Res 2559-565.

18. Cummings SR, Kelsey JL, Nevitt MC O'Dowd KJ 1985 Epidemiology

of osteoporosis and osteoporotic fractures. Epidemiol Rev
7: 178-208.

(19) M. J. Rothmann, P. R. Jakobsen, C. M. Jensen, A. P. Hermann, A. C Smith and J.

Clemensen, Experiences of being diagnosed with osteoporosis: a meta-synthesis, Archives of
Osteoporosis, 10.1007/s11657-018-0436-6, 13, 1, (2018).

21 Osteoporosis overview. NIH Osteoporosis and Related Bone Diseases National Resource
Center. https://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/overview.asp. Accessed
July 19, 2017.
22. O'Neill S, Eden J. The pathophysiology of menopausal symptoms. Obstetrics, Gynaecology
& Reproductive Medicine. 2017 Aug 2.

23. North American Menopause Society: Recommendations for estrogen and progestogen use in
peri-and postmenopausal women: October 2004 position statement of The North American
Menopause Society, Menopause 2004, 11(6 Pt 1):589-600.

24. . Zhao R. Immune regulation of bone loss by Th17 cells in oestrogen‐deficient osteoporosis.
European journal of clinical investigation. 2013 Nov;43(11):1195-202.

25. Elena Rezuș , Reumatologie, ed. ”Gr. T. Popa ” UMF Iași, 2014, 238-247
1. Kanis,J.A., McCloskey,E.V., Johansson,H., Cooper,C., Rizzoli,R., & Reginster,J.Y. (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal
women. Osteoporos.Int. 24, 23-57.
2. Kannus,P., Sievanen,H., Palvanen,M., Jarvinen,T., & Parkkari,J. (2005) Prevention of falls
and consequent injuries in elderly people. Lancet 366, 1885-1893.
3. Cranney,A., Guyatt,G., Griffith,L., Wells,G., Tugwell,P., & Rosen,C. (2002) Meta-analyses
of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies
for postmenopausal osteoporosis. Endocr.Rev. 23, 570-578.
4. Cosman,F., de Beur,S.J., LeBoff,M., Lewiecki,E.M., Tanner,B., Randall,S., & Lindsay,R.
(2014) Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos.Int. 25.

26 . 39. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for
prevention of fractures în postmenopausal women with osteoporosis. N
Engl J Med 2009; 361:756.
27 40. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of
denosumab and alendronate on DMO and biochemical markers of bone blinded, phase 3 trial.
J Bone Miner Res 2009; 24:153.
28 41. Kendler D.L., Roux C., Benhamou C.L., et al. Effects of denosumab
on bone mineral density and bone turnover în postmenopausal women
transitioning from alendronate therapy. J Bone Miner Res 2010; 25:72.
29 42. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on
bone mineral density and bone turnover în postmenopausal women.
J Clin Endocrinol Metab 2008; 93:2149.
30 43. Eric Orwoll, Christence S. Teglbjærg, Bente L. Langdahl et al. A
Randomized, Placebo-Controlled Study of the Effects of Denosumab
for the Treatment of Men with Low Bone Mineral Density. JCEM 2012;
97:3161-3169;doi:10.1210/jc.2012-1569.
31 44. Smith M.R., Egerdie B., Hernández Toriz N., et al. Denosumab în men
receiving androgen-deprivation therapy for prostate cancer. N Engl J Med
2009; 361:745.
32 45. Highlights of prescribing information, Prolia (denosumab) http://
pi.amgen.com/united_states/prolia/prolia_pi.pdf.
33 46. Gerstenfeld L.C., Sacks D.J., Pelis M, et al. Comparison of effects of
the bisphosphonate alendronate versus the RANKL inhibitor denosumab
on murine fracture healing. J Bone Miner Res 2009; 24:196.

34 47. Rodríguez J.P., Montecinos L., Ríos S. et al. Mesenchymal stem cells
from osteoporotic patients produce a type I collagen-defi cient extracellular
matrix favoring adipogenic differentiation. J Cell Biochem. 2000;
79(4):557–565.
35 48. Verma S., Rajaratnam J.H., Denton J. et al. Adipocytic proportion of
bone marrow is inversely related to bone formation în osteoporosis. J Clin
Pathol. 2002; 55(9):693–698.
36 49. Mayr-Wohlfart U., et al. Vascular endothelial growth factor stimulates
chemotactic migration of primary human osteoblasts. Bone 2002;
30(3):472–477.
38 50. Hiltunen M.O., et al. Adenovirus-mediated VEGF-A gene transfer induces
bone formation în vivo. FASEB J. 2003; 17(9):1147–1149.
39 51. Midy V., Plouet J. Vasculotropin/vascular endot helial growth factor
induces differentiation în cultured osteoblasts. Biochem Biophys Res
Commun. 1994; 199(1):380–386.
40 52. Wilson A., Shehadeh L.A., Yu H., Webster K.A. Age-related molecular
genetic changes of murine bone marrow mesenchymal stem cells. BMC
Genomics. 2010; 11:229.
41 53. Yanqiu Liu, Agnes D. Berendsen, Shidong Jia et al. Intracellular VEGF
regulates the balance between osteoblast and adipocyte differentiation. J
Clin Invest. 2012; 122(9):3101–3113 doi:10.1172/JCI61209.
42 54. Van der Flier A., Sonnenberg A. Function and interaction of integrins.
Cell Tissue Res 2001; 305:285–298.
43 55. Rodan S.B., Rodan G.A. Integrin function în osteoclasts. J Endocrinol
1997; 154:S47–S56.
44 56. Murphy M.G., Cerchio K., Stoch S.A., et al. Effect of L-000845704, an
alphaVbeta3 integrin antagonist, on markers of bone turnover and bone
mineral density în postmenopausal osteoporotic women. J Clin Endocrinol
Metab 2005; 90:2022.
45 57. Nishi Y., Atley L., Eyre D.E., et al. Determination of bone markers
în pycnodysostosis: effects of cathepsin K defi ciency on bone matrix
degradation. J Bone Miner Res. 1999; 14:1902–1908.
46 58. Eastell R., Nagase S., Ohyama M., et al. Safety and effi cacy of the
cathepsin K inhibitor ONO-5334 în postmenopausal osteoporosis: the
OCEAN study. J Bone Miner Res 2011; 26:1303.

47. Ettinger B, Black DM, Litlak BH et al- Reduction of vertebral fracture risk in
postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year
randomized clinical trial. Multiple outcomes of Raloxifene Evaluation, JAMA 1999; 282:
637-645;
48 Lawrence G. Raisz - Pathogenesis of osteoporosis: concepts, conflicts, and prospects J
Clin Invest. 2005;115(12):3318-3325

49 Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: principal results from the Women`s Health
Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
50 Xiaodong Li , Michael S Ominsky , Kelly S Warmington , Sean Morony , Jianhua
Gong , Jin Cao , Yongming Gao , Victoria Shalhoub , Barbara Tipton , Raj Haldankar ,
Qing Chen , Aaron Winters, Tom Boone , Zhaopo Geng , Qing‐Tian Niu , Hua Zhu Ke ,
Paul J Kostenuik , W Scott Simonet , David L Lacey , Chris Paszty - Sclerostin
Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat
Model of Postmenopausal Osteoporosis , 2009.
1 Stepnick LS 2004 The frequency of bone disease. In: MacGowan JALGR, Noonan AS,
Elderkin AL (eds). Bone Health and Osteoporosis: A Report of Surgeon General Washington, DC,
USA, 68–87.

2 Shoback D 2007 Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol
Metab92: 747–753.

Introducere ce am scos

Reid a studiat relaţia între ţesutul adipos şi os. Astfel autorul arată în lucrarea sa că
greutatea corporală are impact atât asupra turnover-ului osos cât şi asupra densităţii osoase,
fiind un important factor de risc pentru fracturile vertebrale şi de şold. Greutatea corporală
influenţează atât prin masa grasă cât şi prin masa slabă densitatea minerală osoasă. Masa
grasă acţionează prin mai multe mecanisme, odată prin presiunea scheletală ce o exercită, apoi
prin asocierea cu secreţia de hormoni activi pe os de către celulele beta pancreatice ca:
insulina, amilina, precum şi secreţia de către adipocite: a estrogenilor şi leptinei (Reid
2008).[10]
Actual este mai puţin clar modul în care diferite compartimente ale organismului
influenţează masa osoasă, uneori rezultatele diferitelor studii fiind conflictuale. Datele din
literatură demonstrează că masa slabă este un factor de predicţie mai bun pentru masa osoasă
decât masa grasă şi greutatea corporală totală, atât la femeile pre cât si postmenopauzale. Alţi
autori descriu masa slabă ca fiind mai predictivă la femei decât la bărbaţi (Jankowska şi colab.
2001).[10]